Overview

Pharmacodynamics, Safety/Tolerability and Efficacy of Topical Omiganan in Patients With uVIN

Status:
Completed
Trial end date:
2017-07-04
Target enrollment:
Participant gender:
Summary
To assess the pharmacodynamics, safety/tolerability and efficacy of topical Omiganan (CLS001) in patients with usual type vulvar intraepithelial neoplasia (uVIN).
Phase:
Phase 2
Details
Lead Sponsor:
Cutanea Life Sciences, Inc.
Maruho Co., Ltd.